Amneal Closes Kashiv BioSciences Deal, Building Global Biosimilar Powerhouse
AMRX has more than doubled off its 52-week low of $8.01.
Summary
Amneal completed its acquisition of Kashiv BioSciences, creating a fully integrated biosimilar platform with R&D, manufacturing, and commercial capabilities. The deal, approved by shareholders on July 31, adds a major long-term growth pillar targeting over $300 billion in projected biologic loss-of-exclusivity through the 2030s. Integration is underway, leveraging a decade-long relationship between the companies. This follows strong Q2 results and a recent term loan repricing, strengthening Amneal's financial position as it scales its biosimilar pipeline.
At the time of this announcement, AMRX was trading at $18.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $8.01 to $19.26. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.